NICE Guidance - December 2024
The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of December 2024. This month there are four guidelines that impact upon primary care.
The Urinary tract infection (recurrent): antimicrobial prescribing guideline has been updated. It sets out sets out an antimicrobial prescribing strategy for preventing recurrent urinary tract infections in children, young people and adults who do not have a catheter. This update makes new recommendations on methenamine hippurate as a preventative treatment and amends existing recommendations on referral and seeking specialist advice, oestrogen for prevention, and choice of antibiotic or antiseptic prophylaxis.
The Tirzepatide for managing overweight and obesity technology appraisal has been published. Tirzepatide is recommended as an option for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults, only if they have:
- an initial body mass index (BMI) of at least 35 kg/m2 and
- at least 1 weight-related comorbidity.
It is recommended to use a lower BMI threshold (usually reduced by 2.5 kg/m2) for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean ethnic backgrounds. If less than 5% of the initial weight has been lost after 6 months on the highest tolerated dose, a decision should be made on whether to continue treatment, taking into account the benefits and risks of treatment for the person.
It should be noted that the usual 90 period for implementation has been extended to 180 days with a further 3 year period to increase eligibility in stages based on health need and clinical benefit. It is also predicted that is could take up to 9 years to create a mature treatment pathway for obesity in primary care.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
| « SMC Update - December 2024 |
Leave a Comment